Skip to contentP
Precision Biosciences Inc
P
DTILPrecision Biosciences Inc Q4 2021 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$6.34M$6.34Mderived−28.3% vs Q4 2020 Net Income-$22.29M-$22.29MderivedN/M vs Q4 2020 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Precision Biosciences Inc · CIK 1357874 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$30,724,000N/M Operating Cash Flowderived-$23,681,000N/M Free Cash Flowderived-$25,186,000N/M Margins · derivedOperating margin-484.7%−219.3 pt vs Q4 2020
Net margin-351.6%−86.5 pt vs Q4 2020
ended Dec 31, 2021 · filed Mar 15, 2022 · 74 d after period end